EGAPP

AcronymDefinition
EGAPPEvaluation of Genomic Applications in Practice and Prevention
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome.
([dagger]) The EGAPP Working Group was established in 2005 to support the development of a systematic process for assessing the available evidence regarding the validity and utility of rapidly emerging genetic tests for clinical practice.
In the 2007 report, EGAPP examined the usefulness of genetic testing for cytochrome P450 (CYP450) before prescribing SSRI antidepressants.
The biggest problem facing EGAPP is the genetic testing deluge.
* The EGAPP Working Group is established to support the development of a systematic process for assessing the available evidence regarding the validity and utility of rapidly emerging genetic tests for clinical practice.
In December, EGAPP published a report on genomic profiling to assess cardiovascular risk (Genet.
Testing for Lynch syndrome is frequently covered by payers, based on the positive evidence review conducted by EGAPP (Evaluation of Genomic Applications in Practice and Prevention).
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group evaluated cytochrome P450 testing and concluded that the evidence does not support its widespread and routine use in patients starting treatment with SSRIs.
Evidence synthesis and review must adhere to evidentiary standards for determining the quality of a specific article, such as those developed the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) group.
(16.) Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.
Some of this has been discussed by the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative and endorsed by the Institute of Medicine Committee in regard to omics-based tests, as well as others, (139) and the Update Committee understands the FDA is developing a risk-based framework to address concerns about test accuracy and clinical utility.